Presepsin as a novel diagnostic biomarker for differentiating active pulmonary tuberculosis from bacterial community acquired pneumonia
- 29 December 2017
- journal article
- research article
- Published by Elsevier in Clinica Chimica Acta
- Vol. 478, 152-156
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Circulating presepsin (soluble CD14 subtype) as a marker of host response in patients with severe sepsis or septic shock: data from the multicenter, randomized ALBIOS trialIntensive Care Medicine, 2014
- Role of Presepsin (sCD14-ST) and the CURB65 scoring system in predicting severity and outcome of community-acquired pneumonia in an emergency departmentRespiratory Medicine, 2014
- Soluble Markers of the Toll-Like Receptor 4 Pathway Differentiate between Active and Latent Tuberculosis and Are Associated with Treatment ResponsesPLOS ONE, 2013
- Role of CD14 in host protection against infections and in metabolism regulationFrontiers in Cellular and Infection Microbiology, 2013
- Guidelines for the management of adult lower respiratory tract infections - Full versionClinical Microbiology and Infection, 2011
- Diagnosis of pulmonary tuberculosis in a microbiological laboratoryMedecine Et Maladies Infectieuses, 2011
- Role of the Clinical Mycobacteriology Laboratory in Diagnosis and Management of Tuberculosis in Low-Prevalence SettingsJournal of Clinical Microbiology, 2011
- Blood cultures for community‐acquired pneumonia: Are they worthy of two quality measures? A systematic reviewJournal of Hospital Medicine, 2009
- Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in AdultsClinical Infectious Diseases, 2007
- Evaluation of a newly identified soluble CD14 subtype as a marker for sepsisJournal of Infection and Chemotherapy, 2005